

Journal Pre-proofs

COVAX – Time to reconsider the strategy and its target

David Bell, Garrett W. Brown, Wellington A. Oyibo, Samiratou Ouédraogo, Blagovesta Tacheva, Elena Barbaud, Andreas Kalk, Valéry Ridde, Elisabeth Paul

PII: S2590-2296(23)00008-4
DOI: <https://doi.org/10.1016/j.hpopen.2023.100096>
Reference: HPOPEN 100096

To appear in: *Health Policy OPEN*

Received Date: 14 November 2022
Revised Date: 29 March 2023
Accepted Date: 3 April 2023

Please cite this article as: D. Bell, G.W. Brown, W.A. Oyibo, S. Ouédraogo, B. Tacheva, E. Barbaud, A. Kalk, V. Ridde, E. Paul, COVAX – Time to reconsider the strategy and its target, *Health Policy OPEN* (2023), doi: <https://doi.org/10.1016/j.hpopen.2023.100096>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 The Author(s). Published by Elsevier B.V.



COVAX – Time to reconsider the strategy and its target

David Bell¹

Garrett W. Brown²

Wellington A. Oyibo³

Samiratou Ouédraogo⁴

Blagovesta Tacheva⁵

Elena Barbaud⁵

Andreas Kalk⁶

Valéry Ridde⁷

Elisabeth Paul⁸

¹ Independent consultant, Lake Jackson, TX, USA, ORCID: 0000-0002-7010-6340

² Professor of Global Health Policy, University of Leeds, United Kingdom, ORCID: 0000-0002-6557-5353

³ Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria, ORCID: 0000-0002-5730-5396

⁴ Observatoire national de la santé de la population (ONSP), Institut National de Santé Publique (INSP), Ouagadougou, Burkina Faso, ORCID: 0000-0001-8224-5543

⁵ Global Health Research Unit, University of Leeds, United Kingdom

⁶ Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ), Kinshasa Country Office, Democratic Republic of the Congo, ORCID: [0000-0002-7039-5066](https://orcid.org/0000-0002-7039-5066)

⁷ Université Paris Cité, IRD, Inserm, Ceped, F-75006 Paris, France, ORCID: 0000-0001-9299-8266

⁸ School of Public Health, Université libre de Bruxelles, Belgium, ORCID: 0000-0002-3928-4093

Correspondence to:

Elisabeth Paul

Campus Erasme, Route de Lennik 808, CP 591, 1070 Brussels, Belgium

Email: Elisabeth.Paul@ulb.be

Phone: +32-2-55.40.12

Word count: 2,502

References: 83

COVAX – Time to reconsider the strategy and its target

Summary

COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion US dollars already committed. While some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. First, mass COVID-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. Second, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. We conclude that the COVAX initiative warrants urgent review.

Introduction

Mass vaccination is a well-evidenced strategy for reducing infectious disease burden and was critical to the eradication of smallpox, and regional elimination of polio and measles. Routine vaccination programs also have an important role in reducing infant and child mortality. With its population-wide approach to a new pathogen, the response to the COVID-19 outbreak is the most rapidly and widely implemented example of a global and horizontal disease control strategy. A major part of this strategy is the Access to COVID-19 Tools Accelerator (ACT-A), and particularly its vaccine pillar, known as COVAX, which involves financial and policy coordination between donors, the World Health Organization (WHO), GAVI, the Coalition for Epidemic Preparedness Innovations (CEPI), and their implementing partner UNICEF (1). As part of COVAX, the global public health community, led by the WHO,

established an 'ambitious' objective: to vaccinate at least 70% of the population in low- and middle-income countries (LMICs) against COVID-19, including those in sub-Saharan Africa. This global target was updated and prioritized in July 2022 in order to achieve "the underpinning targets of vaccinating 100% of health care workers and 100% of the most vulnerable groups, including older populations (over 60s) and those who are immunocompromised or have underlying conditions" (2). This approach is promoted as 'vaccine equity', a novel concept grounded on the huge discrepancies in national COVID-19 vaccination rates. In terms of proposed cost, COVAX is probably the highest-cost international initiative targeting an infectious disease in history, with over US\$ 16 billion already committed, roughly equivalent to three-year's worth of commitment to the Global Fund (3,4), and an estimated cost of universal vaccination with three doses of an mRNA vaccine in low- and lower-middle income countries of US\$61 billion (5).

The 70% target might have been relevant at the time it was set up – it is important to remember that ACT-A launched in April 2020, very early in the pandemic (6) – as an accelerated way of reaching herd immunity without incurring too many human losses. Nevertheless, the situation has changed, our knowledge about COVID-19 immunity has evolved, and thus policies should evolve accordingly (7). Appropriate prioritization of the COVID-19 response in sub-Saharan African countries should be based on the relative impact (direct and indirect) of the pandemic in comparison to populations elsewhere and on other regional health priorities (8). Many authors defend current COVAX strategies, urging the international community to 'achieve global COVID-19 vaccine equity' through mass vaccination (9–11), pointing notably to the higher case fatality rate of COVID-19 in LMICs (12) as well as to the relatively high burden of COVID-19 in terms of excess death in LMICs, particularly in South-East Asia and Latin America (13). However, by late 2021, Africa had a similar number of COVID-19 infections to that of the rest of the world, but with far fewer reported deaths (14). In the first week of January 2023, even if figures are probably under-

reported, the African Region of WHO only recorded 7 deaths from COVID-19 in the past week (15). Some authors suggest to limit vaccination to higher-risk adults and vulnerable children and adolescents (16). Evidence of relatively high burden of COVID-19 among pregnant women in Africa (17) has also prompted calls to prioritize their vaccination (18).

Based on a targeted literature review, this perspective paper complements existing critiques of COVAX, notably on its governance and ownership (6,19), by arguing that the internationally supported target of vaccinating 70% of LMIC populations, including the 1.3 billion sub-Saharan African population, is unjustified on health grounds and likely to result in net harm (reduced health equity). We argue that previous analyses have overlooked two important areas: the very limited actual benefit that most people can now accrue through vaccination, and the opportunity costs of resource diversion in achieving this. We conclude that in Africa, orthodox public health decision criteria suggest that the COVID-19 vaccination strategy should be targeted at those most at-risk – which may not equate to 100% of health workers – and not based on the prevailing logic of mass vaccination campaigns.

COVID-19 mass vaccination in Africa does not meet standard public health decision criteria

Public health policies should reflect a populations' need to attain the best possible health status for those targeted. This also requires responsiveness to people's expectations, equity, financial sustainability, and efficiency (20). To be justified from a public health standpoint, strategies and interventions must be prioritised through an inclusive policy dialogue that weighs relevant decision criteria, including disease burden, the interventions' potential effectiveness, its costs, and its overall impacts on equity (21,22). In most cases, such as in the case of malaria, this is the prevailing logic, where interventions are meant to target specific country disease burdens (23).

In the case of COVID-19, the reported disease burden in sub-Saharan Africa is low (24) and arguments that this is due to under-reporting compared to high-income countries remains weak (9). Differences in population age distributions and the very high age-related heterogeneity in vulnerability to severe COVID-19 predict far lower mortality in most LMICs, (25,26) with 50% of the sub-Saharan population under 19 years of age (27). In contrast, lockdowns, interrupted supply lines and economic decline are expected to disproportionately increase mortality, accounting for much of any all-cause mortality increase (28,29). The reasons WHO previously advised against interruptions to economic health was to prevent such collateral deaths (30). Yet, even when allowing for gross under-reporting, COVID-19 is not one of the dominating disease burdens for African populations based on disability adjusted life years (DALYs), a metric advocated by WHO (31). Moreover, most people in sub-Saharan Africa have already acquired post-infection immunity, especially since the arrival of the highly-transmissible Omicron variant (14,32,33). Countries such as Senegal and Burkina Faso have shown via national seroprevalence surveys that more than 90% of the population had been in contact with the coronavirus by the end of 2021. Post-infection immunity is more effective in blocking infection than the current mRNA vaccines, and there is minimal benefit from vaccinating on top of post-infection immunity (34,35). There is also emerging evidence suggesting that mRNA vaccines have a more limited effect on overall mortality than previously assumed, again requiring a rethink of existing vaccination strategies (36,37). Therefore, with the possible exception of South Africa with its older population and higher comorbidities, the sub-Saharan population is at low risk of developing a severe form of COVID-19. By contrast, African populations are faced with increased risk from malnutrition and endemic infectious diseases including malaria, tuberculosis and HIV/AIDS (25,27,38,39), which impart far higher burdens than COVID-19.

Public health interventions must be demonstrably effective, both for the recipient and the community. We have argued above that the young, healthy and naturally immune population of Africa is at low overall risk of severe COVID-19. They therefore will accrue limited personal benefits from COVID-19 vaccination. Where a large proportion of recipients are at low risk of the disease being prevented, mass vaccination may still be justified (9), but only if it is transmission-blocking (reducing infection in other, high-risk, people). This strategy could also reduce the pool of circulating virus from which variants may arise. However, the COVID-19 vaccines currently available do not block transmission (40–42), and in some populations recorded infections in vaccinated individuals are more frequent than in unvaccinated individuals (43). Vaccination of non-vulnerable people is therefore not expected to impart substantial protection on the vulnerable.

Public health interventions must have sufficiently lasting impact. While post-infection immunity is well sustained (44), a large body of evidence shows that vaccine-induced protection against COVID-19 infection wanes after several months (45,46). Protection against severe disease in the previously non-immune wanes more slowly, but reduces with time, with boosters offering limited recovery of immunity (45,47,48). Mass vaccination therefore will not provide strong long-term vaccine-derived protection to the recipient population without, at least, frequent population-wide boosters, adding significant cost and thereby raising questions of sustainability (49).

Good public health practice requires that total health gains from the intervention must outweigh its costs. This means that significantly fewer recipients will be put at higher health risk from the vaccine than they would be from the pathogen. Net benefit must be even clearer for mass prevention interventions. Due to the extreme heterogeneity of risk for severe COVID-19 (25), such assessments must consider the varying risk profiles of each population and vaccine type (50,36,51). The safety of COVID-19 vaccines is a complex area and dealt with extensively elsewhere (52–56). It

is clear they are not free of severe side-effects, and that voluntary reporting systems register associated adverse events at a rate higher than other vaccines (57–59). In particular, significant rates of myocarditis are recorded in young males (60–62) and considerable associated mortality is recorded in the VAERS (63) and EudraVigilance (64) databases. While causality is in dispute, the associated rate is far higher than reported for influenza vaccines. Being of a pharmaceutical class not previously used widely in humans, the mRNA vaccines also have no vaccine-specific or class-specific safety data. This, together with the reduced capacity in LMICs to monitor and manage adverse events, raises medical ethics questions concerning use of such a pharmaceutical in individuals who will accrue minimal direct benefit. As the expected benefit of COVID-19 vaccination in already-immune young African populations is very limited, the risk-benefit balance of COVID-19 vaccines is at best unclear (65).

Some voices have presented COVID-19 “vaccine equity” as a step towards decolonisation and the advancement of human rights (66–68). These are important concepts in global health and should be taken seriously. Nevertheless, in the case of COVID-19 vaccines, these voices are seemingly most concerned with existing inequalities in terms of access to medicines (writ large) as a symptom of unfair distributive models. What these voices ignore, however, is the difference between *access to medicines* (as a general problem in global health) with *access to the right medicines* (an intervention that will actually advance general health equity). Consequently, COVAX and COVID-19 vaccines have seemingly become a battlefield for the much larger and necessary fight about access, but in doing so, have failed to recognize that access should reflect need and expected health outcomes, especially we argue, in the case of COVID in Africa.

Moreover, it is also important to consider that other human rights need to be strongly considered when examining potential knock-on effects of promoting broad inoculation targets and their associated enforcement mechanisms, including the

need for informed consent and absence of legal or social coercion (69). For example, in Benin, Ghana and Nigeria, there have been categories of people (e.g. civil servants, medical, paramedical, pharmacist and nursing staff, administrative staff of public and private health facilities) pressured or obliged to get vaccinated against COVID-19 (70–72). Without going back over the history of medicine in Africa, one has to note the coercive approach used during colonialism, which did not respect human rights and which is still remembered (73). With few exceptions, modern vaccine programmes have been voluntary and do not restrict participation in society, yet there have been at times a worrying imbalance in soft and hard regulatory coercion measures as well as social stigma / exclusion associated with incentivising COVID-19 vaccinations in the face of vaccine hesitancy.

Human rights are a complex but important area, and are not dealt with here beyond noting that as COVID-19 vaccination will not protect others, arguments for imposition under emergency conditions for that purpose are very weak and we must be aware of the potential harmful impacts of legal and social stigmatisation (74). Moreover, ethical considerations in public health emphasize the precautionary principle and stress locally-tailored approaches in mass vaccinations (75). It is perhaps from this perspective that we can understand the important discrepancies observed in countries such as Benin and Senegal, where the levels of (declarative) intention to vaccinate against COVID-19 are very high (around 70%), but the actual uptake of vaccination is very low (around 10%) (76).

The opportunity cost of COVID-19 mass vaccination runs against health equity

It is of crucial importance not to consider the resources dedicated to COVID-19 vaccination, both financial and human, in isolation. Each could have been invested in alternatives; what economists refer to as 'opportunity costs'. The choice of the appropriate mix of health interventions to be included in a national strategy must be

decided on a case-by-case basis, normally considering these costs, and relative disease burden, through a policy dialogue with the stakeholders (21). Mass COVID-19 vaccination will not only involve diverting resources from interventions targeting greater health burdens (including routine children vaccination programmes), but also from 'horizontal' strengthening of health systems necessary for these interventions to succeed (77).

For example, each year the entire global budget for malaria is approximately \$3 billion (78). Africa CDC estimated that \$10 billion would be required to support two COVID-19 vaccination campaigns on the continent (79). As of November 22, 2022, \$16.2 billion had been allocated to the vaccine pillar of ACT-A for all LMICs (3). Other estimates suggest \$35.5 billion would be needed to vaccinate everyone in LMICs, increasing to over \$60 billion with a booster (5); or that \$74 billion would be needed to reach presumed herd immunity through vaccination in LMICs (80). These are staggering sums, and in the case of COVID-19, for a short-term intervention. By contrast, the entire Global Fund annual dispersal is currently slightly above \$5 billion per year for malaria, tuberculosis and HIV/AIDS combined (4), the estimated burden of each of which dwarfs the COVID-19 burden in these populations (38). A study in Kenya estimates the total economic cost of procurement and delivery of COVID-19 vaccines, per person vaccinated with 2-doses, between \$29.7-\$24.68 for 30% and 100% population coverage respectively (81). This amounts to about one third of the current total annual health expenditure per capita (82). WHO and UNICEF recently warned that pandemic disruptions and diversion of resources from routine immunization leave millions of children worldwide without protection against measles and other vaccine-preventable diseases (83). In terms of cost-effectiveness, a recent study estimated a cost-per-COVID-19 death averted through universal mRNA vaccination in LMICs of US\$40 800 (US\$7 400–US\$81 500), with several likely factors (lower infection fatality ratios, lower vaccine effectiveness or uptake) leading to higher estimates (5). This is considerably higher than acceptable cost-effectiveness

thresholds in LMICs (84). By comparison, in Zambia, active case finding of tuberculosis is estimated to incur an incremental cost of US\$2 284 per death averted (85).

In addition, there are worrying signs that financial and resource reallocations to COVID-19 vaccine strategies are already significantly short-changing other health subsystems, threatening UHC vulnerabilities. For example, the Development Assistance Committee of the Organization for Economic Cooperation and Development (OECD DAC) annual data on Overseas Development Assistance (ODA) saw a total donor disbursement of US\$4.4 billion on COVID-19 related activities in 2020, representing the largest increase of ODA in history. Yet, despite this overall increase, when compared to 2019, OECD DAC ODA for basic health care dropped by 34.5% and basic nutrition by 10.1% (86,87). Other studies suggest that total development spending for COVID-19 exceeded US\$13.7 billion, with an estimated US\$1.4 billion 'repurposed' from existing health sector commitments, again confirming that a level of resource reallocation has taken place (88). Further evidence suggests that funds are being diverted from other high-burden diseases, such as malaria (89), TB (90), and HIV (91), while a study in Ghana determined that COVID-19 prioritizations and reallocations have had an adverse effect on overall health financing and the national strategic plan (92). Moreover, there are a number of reported secondary effects on health systems and outcomes due to COVID-19 vaccine prioritizations, particularly related to malaria (93), TB (94), sexual and reproductive health and HIV (95), noncommunicable diseases (96), and neglected tropical diseases (97). Lastly, there is clear evidence of task-shifting, where medical personnel are being reassigned from other health subsystems to COVID-19 vaccination activities. In the case of Indonesia, the diversion of human resources to pandemic response efforts disrupted polio immunisation services, putting the country's polio-free status at risk (98).

These costs raise significant questions in terms of cost-effectiveness and health equity. In our case, this consists in comparing the benefits of COVID-19 vaccination (in terms of avoided COVID-19 deaths and/or hospitalisations) to the total costs of vaccination, including in terms of resource use (vaccine procurement and health system-related), resource reallocations, diversions in health financing, secondary effects on health systems, and opportunity costs. It also consists in comparing the population health benefits of COVID-19 vaccination to overall population health access, outcomes and quality of care. When taken as a whole, we argue that the proposed costs for COVID-19 mass vaccination are greatly disproportionate to the disease burden with significant cost to other health initiatives and health system needs. Taken with the limited duration for protection the vaccines offer against COVID-19, and the small proportion of the population who remain non-immune and are intrinsically susceptible, mass vaccination appears to constitute poor resource stewardship that threatens wider population health needs and UHC vulnerabilities.

Conclusion

On orthodox public health criteria (need, impact, efficiency, equity), the case for mass-vaccination of populations in Africa against COVID-19 is weak. Most people in these populations already have immunity as effective as that which vaccination could provide. The vaccines do not prevent transmission to the relatively small pool of highly vulnerable people who may still be non-immune and at high risk. The diversion of resources, far higher than allocated to any other disease, or to general health system strengthening or universal health coverage, will inevitably impose (and already have imposed) a large opportunity cost on health system capacities and thus on management of other diseases, and potentially on the economies on which future disease control will depend.

The COVAX programme is being touted as promoting 'equity', but equal access to a pharmaceutical product is not health equity. The latter requires equal access to an

opportunity for a healthy life (99). Moreover, it is important not to confuse the clear unfairness associated with 'vaccine nationalism' (which we strongly deplore) and persistent blockages to medicines writ large (which underwrite feelings of injustice at the heart of most COVAX 'equity' arguments) with the fact that, in this particular case, a population-wide COVID-19 vaccine programme will not contribute to the equitable promotion of public health. COVAX therefore appears misdirected, and a return to the principles of public health, including resource allocation based on disease burden and actual risk would bring better health outcomes for the populations to whom it is directed. Consequently, in re-considering the strategies and targets for COVAX in the lens of public health equity and opportunity costs, country-wide mandatory COVID-19 vaccinations across population groups is unwarranted, unsustainable and will degrade already weakened health systems. This has implications for reflections about current and future COVAX policy as well as for ongoing debates about its future or its replacement by a different COVID-19 vaccine pooling mechanism. Within these policy debates we believe that allowing space for a more a case-by-case approach is preferable in LMIC settings, where country stakeholder dialogue is paramount, especially much of Africa, where COVID-19 mass vaccination makes little sense, yet comes at great cost.

References

1. World Health Organization. COVAX - Working for global equitable access to COVID-19 vaccines [Internet]. 2022 [cited 2022 Jan 19]. Available from: <https://www.who.int/initiatives/act-accelerator/covax>
2. World Health Organization. WHO releases global COVID-19 vaccination strategy update to reach unprotected [Internet]. 2022 [cited 2023 Jan 5]. Available from: <https://www.who.int/news/item/22-07-2022-who-releases-global-covid-19-vaccination-strategy-update-to-reach-unprotected>
3. World Health Organization. Access to COVID-19 tools funding commitment tracker [Internet]. 2022 [cited 2023 Jan 6]. Available from: <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>

4. The Global Fund. Seventh Replenishment - Fight for What Counts [Internet]. 2022 [cited 2023 Jan 6]. Available from: <https://www.theglobalfund.org/en/seventh-replenishment/>
5. Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J, et al. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. *BMJ Open* [Internet]. 2022;12(9). Available from: <https://bmjopen.bmj.com/content/12/9/e061752>
6. Open Consultants. External Evaluation of the Access To COVID-19 Tools Accelerator (ACT-A) [Internet]. 2022 Oct. Available from: [https://www.who.int/publications/m/item/external-evaluation-of-the-access-to-covid-19-tools-accelerator-\(act-a\)](https://www.who.int/publications/m/item/external-evaluation-of-the-access-to-covid-19-tools-accelerator-(act-a))
7. Paul E, Brown GW, Kalk A, Van Damme W, Ridde V, Sturmberg JP. "When My Information Changes, I Alter My Conclusions." What Can We Learn from the Failures to Adaptively Respond to the SARS-Cov-2 Pandemic and the Under Preparedness of Health Systems to Manage COVID-19? *Int J Health Policy Manag*. 2020;
8. Bwire G, Ario AR, Eyu P, Ocom F, Wamala JF, Kusi KA, et al. The COVID-19 pandemic in the African continent. *BMC Med* [Internet]. 2022 May 2;20(1):167. Available from: <https://doi.org/10.1186/s12916-022-02367-4>
9. Yamey G, Garcia P, Hassan F, Mao W, McDade KK, Pai M, et al. It is not too late to achieve global covid-19 vaccine equity. *BMJ*. 2022 Mar 24;376:e070650.
10. Sam-Agudu NA, Quakyi NK, Masekela R, Zumla A, Nachega JB. Children and adolescents in African countries should also be vaccinated for COVID-19. *BMJ Glob Health* [Internet]. 2022 Feb 1;7(2):e008315. Available from: <http://gh.bmj.com/content/7/2/e008315.abstract>
11. Nachega JB, Sam-Agudu NA, Macheke RN, Rabie H, van der Zalm MM, Redfern A, et al. Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries. *JAMA Pediatr* [Internet]. 2022 Jan 19 [cited 2022 Feb 14]; Available from: <https://doi.org/10.1001/jamapediatrics.2021.6436>
12. Levin AT, Owusu-Boaitey N, Pugh S, Fosdick BK, Zwi AB, Malani A, et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. *BMJ Glob Health* [Internet]. 2022 May 1;7(5):e008477. Available from: <http://gh.bmj.com/content/7/5/e008477.abstract>
13. Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. *Nature* [Internet]. 2023 Jan 1;613(7942):130–7. Available from: <https://doi.org/10.1038/s41586-022-05522-2>
14. Cabore JW, Karamagi HC, Kipruto HK, Mungatu JK, Asamani JA, Droti B, et al. COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past trends and future patterns. *Lancet Glob Health* [Internet]. [cited 2022 Jul 4]; Available from: [https://doi.org/10.1016/S2214-109X\(22\)00233-9](https://doi.org/10.1016/S2214-109X(22)00233-9)
15. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2023 Jan 6]. Available from: <https://covid19.who.int/table>

16. Govender K, Nyamaruze P, McKerrow N, Meyer-Weitz A, Cowden RG. COVID-19 vaccines for children and adolescents in Africa: aligning our priorities to situational realities. *BMJ Glob Health* [Internet]. 2022 Feb 1;7(2):e007839. Available from: <http://gh.bmj.com/content/7/2/e007839.abstract>
17. Nachega JB, Sam-Agudu NA, Machekano RN, Rosenthal PJ, Schell S, de Waard L, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Pregnancy in Sub-Saharan Africa: A 6-Country Retrospective Cohort Analysis. *Clin Infect Dis* [Internet]. 2022 Jun 8 [cited 2022 Apr 7];ciac294. Available from: <https://doi.org/10.1093/cid/ciac294>
18. Nachega JB, Sam-Agudu NA, Siedner MJ, Rosenthal PJ, Mellors JW, Zumla A, et al. Prioritizing Pregnant Women for Coronavirus Disease 2019 Vaccination in African Countries. *Clin Infect Dis* [Internet]. 2022 Jun 8 [cited 2022 Apr 7];ciac362. Available from: <https://doi.org/10.1093/cid/ciac362>
19. Storeng KT, de Bengy Puyvallée A, Stein F. COVAX and the rise of the ‘super public private partnership’ for global health. *Glob Public Health* [Internet]. 2021 Oct 22;1–17. Available from: <https://doi.org/10.1080/17441692.2021.1987502>
20. de Savigny D, Adam T. Systems Thinking for Health Systems Strengthening [Internet]. Alliance for Health Policy and Systems Research and World Health Organization; 2009. Available from: <http://www.who.int/alliance-hpsr/resources/9789241563895/en/>
21. Schmets G, Rajan D, Kadandale S. Strategizing national health in the 21st century: a handbook. Geneva, Switzerland: World Health Organization;
22. World Health Organization. Making fair choices on the path to universal health coverage. Final report of the WHO Consultative Group on Equity and Universal Health Coverage [Internet]. World Health Organization; 2014 [cited 2017 Nov 13]. Available from: http://www.who.int/choice/documents/making_fair_choices/en/
23. World Health Organization, RBM Partnership to End Malaria. High burden to high impact: a targeted malaria response [Internet]. World Health Organization; 2018 Nov. Report No.: WHO/CDS/GMP/2018.25 Rev 1. Available from: <https://www.who.int/publications/i/item/WHO-CDS-GMP-2018.25>
24. Africa CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. 2022 [cited 2022 May 10]. Available from: <https://africacdc.org/covid-19/>
25. Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. *The Lancet* [Internet]. [cited 2022 Apr 6]; Available from: [https://doi.org/10.1016/S0140-6736\(21\)02867-1](https://doi.org/10.1016/S0140-6736(21)02867-1)
26. Centers for Disease Control and Prevention (CDC). COVID-19 Risk Factor for Severe Diseases, Race, and Age [Internet]. 2021. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/downloads/covid-data/hospitalization-death-by-age.pdf>
27. United Nations. World Population Prospects 2019 [Internet]. Department of Economic and Social Affairs. 2022 [cited 2022 Apr 7]. Available from: <https://population.un.org/wpp/Download/Standard/Population/>

28. UNICEF. Preventing a lost decade: Urgent action to reverse the devastating impact of COVID-19 on children and young people [Internet]. 2021 Dec. Available from: <https://www.unicef.org/media/112891/file/UNICEF%2075%20report.pdf>
29. Global Financing Facility. Emerging data estimates that for each COVID-19 death, more than two women and children have lost their lives as a result of disruptions to health systems since the start of the pandemic [Internet]. 2021. Available from: <https://www.globalfinancingfacility.org/emerging-data-estimates-each-covid-19-death-more-two-women-and-children-have-lost-their-lives-result>
30. World Health Organization GIP. Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza [Internet]. 2019. Available from: <https://apps.who.int/iris/bitstream/handle/10665/329438/9789241516839-eng.pdf?ua=1>
31. Murray CJL, Lopez AD. Measuring the Global Burden of Disease. *N Engl J Med*. 2013 Aug 1;369(5):448–57.
32. Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, et al. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. Adamou R, Adegnikaa AA, Assoumou SZ, Audu RA, Barnor JS, Birru E, et al., editors. *BMJ Glob Health* [Internet]. 2022;7(8). Available from: <https://gh.bmj.com/content/7/8/e008793>
33. Institute for Health Metrics and Evaluation (IHME). COVID-19 Results Briefing - The African Region [Internet]. 2022 Feb. Available from: https://www.healthdata.org/sites/default/files/files/Projects/COVID/2022/44563_briefing_African_Region_1.pdf
34. León T, Dorabawila V, Nelson L, et al. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021 [Internet]. Centers for Disease Control and Prevention; 2022 Jan. Report No.: 71: 125-131. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e1.htm?s_cid=mm7104e1_w
35. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. *The Lancet* [Internet]. 2022 Feb 4; Available from: <https://www.sciencedirect.com/science/article/pii/S0140673622000897>
36. Benn CS, Scholtz-Buchholzer F, Nielsen S, Netea MG, Aaby P. Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects? [Internet]. Preprint with *The Lancet*; 2022 [cited 2022 May 10]. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4072489
37. Au WY, Cheung PPH. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. *BMJ* [Internet]. 2022 May 31;377:e069989. Available from: <http://www.bmj.com/content/377/bmj-2022-069989.abstract>
38. Bell D, Schultz Hansen K. Relative Burdens of the COVID-19, Malaria, Tuberculosis, and HIV/AIDS Epidemics in Sub-Saharan Africa. *Am J Trop Med Hyg*. 2021 Dec 1;105(6):1510–5.

39. Fore HH, Dongyu Q, Beasley DM, Ghebreyesus TA. Child malnutrition and COVID-19: the time to act is now. *The Lancet* [Internet]. 2020 Aug 22 [cited 2022 Apr 6];396(10250):517–8. Available from: [https://doi.org/10.1016/S0140-6736\(20\)31648-2](https://doi.org/10.1016/S0140-6736(20)31648-2)
40. Franco-Paredes C. Transmissibility of SARS-CoV-2 among fully vaccinated individuals. *Lancet Infect Dis* [Internet]. 2022 Jan 1 [cited 2022 Jan 19];22(1):16. Available from: [https://doi.org/10.1016/S1473-3099\(21\)00768-4](https://doi.org/10.1016/S1473-3099(21)00768-4)
41. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. *N Engl J Med* [Internet]. 2022 Jan 5 [cited 2022 Feb 15]; Available from: <https://doi.org/10.1056/NEJMoa2116597>
42. Boucau J, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, et al. Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection. *N Engl J Med* [Internet]. 2022 Jun 29 [cited 2022 Jul 4]; Available from: <https://doi.org/10.1056/NEJMc2202092>
43. UK Health Security Agency. COVID-19 vaccine surveillance report - Week 13 [Internet]. 2022 Mar [cited 2022 Apr 7]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1066759/Vaccine-surveillance-report-week-13.pdf
44. Radbruch A, Chang HD. A long-term perspective on immunity to COVID. *Nature* [Internet]. 2021;595(359–360). Available from: <https://www.nature.com/articles/d41586-021-01557-z>
45. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. *The Lancet* [Internet]. 2022 Feb 4; Available from: <https://www.sciencedirect.com/science/article/pii/S0140673622000897>
46. Chemaitelly H, Abu-Raddad LJ. Waning effectiveness of COVID-19 vaccines. *The Lancet*. 2022 Feb 26;399(10327):771–3.
47. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. *Lancet Infect Dis* [Internet]. 2022 Apr 6 [cited 2022 Apr 6]; Available from: [https://doi.org/10.1016/S1473-3099\(22\)00143-8](https://doi.org/10.1016/S1473-3099(22)00143-8)
48. Nordström P, Ballin M, Nordström A. Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study [Internet]. 2021. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3949410
49. Savinkina A, Bilinski A, Fitzpatrick MC, Paltiel AD, Rizvi Z, Salomon JA, et al. Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era. *medRxiv* [Internet]. 2022 Jan 1;2022.02.08.22270465. Available from: <http://medrxiv.org/content/early/2022/02/09/2022.02.08.22270465.abstract>
50. Nohynek H, Wilder-Smith A. Does the World Still Need New Covid-19 Vaccines? *N Engl J Med* [Internet]. 2022 May 4 [cited 2022 May 10]; Available from: <https://doi.org/10.1056/NEJMe2204695>

51. Eick-Cost AA, Ying S, Wells N. Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant. *JAMA Netw Open* [Internet]. 2022 Apr 20 [cited 2022 Oct 5];5(4):e228071–e228071. Available from: <https://doi.org/10.1001/jamanetworkopen.2022.8071>
52. Rosenblum HG, Gee J, Liu R, Marquez PL, Zhang B, Strid P, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. *Lancet Infect Dis* [Internet]. [cited 2022 May 10]; Available from: [https://doi.org/10.1016/S1473-3099\(22\)00054-8](https://doi.org/10.1016/S1473-3099(22)00054-8)
53. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. *JAMA Netw Open* [Internet]. 2021 Dec 22 [cited 2022 Oct 5];4(12):e2140364–e2140364. Available from: <https://doi.org/10.1001/jamanetworkopen.2021.40364>
54. Sun CLF, Jaffe E, Levi R. Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave. *Sci Rep*. 2022;12(1):6978.
55. Chua GT, Kwan MYW, Chui CSL, Smith RD, Cheung ECL, Ma T, et al. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. *Clin Infect Dis* [Internet]. 2021 Nov 28 [cited 2022 Feb 15];ciab989. Available from: <https://doi.org/10.1093/cid/ciab989>
56. Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, et al. Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials [Internet]. 2022. Available from: <https://ssrn.com/abstract=4125239>
57. Centers for Disease Control and Prevention (CDC). Vaccine Adverse Event Reporting System (VAERS) [Internet]. 2022 [cited 2022 Apr 7]. Available from: <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html>
58. EudraVigilance. European database of suspected adverse drug reaction reports [Internet]. Available from: https://www.adrreports.eu/en/search_subst.html
59. Montano D. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States. *Front Public Health* [Internet]. 2022;9. Available from: <https://www.frontiersin.org/article/10.3389/fpubh.2021.756633>
60. Lai FTT, Li X, Peng K, Huang L, Ip P, Tong X, et al. Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine. *Ann Intern Med* [Internet]. 2022 Jan 25 [cited 2022 Feb 15]; Available from: <https://doi.org/10.7326/M21-3700>
61. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med* [Internet]. 2021 Dec 14; Available from: <https://doi.org/10.1038/s41591-021-01630-0>
62. Chua GT, Kwan MYW, Chui CSL, Smith RD, Cheung ECL, Ma T, et al. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. *Clin Infect Dis*. 2021 Nov 28;ciab989.

63. Centers for Disease Control and Prevention (CDC). Vaccine Adverse Event Reporting System (VAERS) [Internet]. [cited 2022 Apr 7]. Available from: <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html>
64. EudraVigilance. European database of suspected adverse drug reaction reports [Internet]. Available from: https://www.adrreports.eu/en/search_subst.html
65. Federal Institute for Vaccines and Biomedicines - Paul-Ehrlich-Institut. Safety Report [Internet]. Langen; 2022 May. Available from: https://www.pei.de/SharedDocs/Downloads/EN/newsroom-en/dossiers/safety-reports/safety-report-27-december-2020-31-march-2022.pdf?__blob=publicationFile&v=7
66. Borges LC, Zeferino de Menezes H, Crosbie E. More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap. *Int J Health Policy Manag* [Internet]. 2022;11(12):3101–13. Available from: https://www.ijhpm.com/article_4301.html
67. Fajber K. Business as Usual? Centering Human Rights to Advance Global COVID-19 Vaccine Equity Through COVAX. *Health Hum Rights*. 2022 Dec;24(2):219–28.
68. Sekalala S, Forman L, Hodgson T, Mulumba M, Namyalo-Ganafa H, Meier BM. Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine. *BMJ Glob Health* [Internet]. 2021 Jul 1;6(7):e006169. Available from: <http://gh.bmj.com/content/6/7/e006169.abstract>
69. Gostin LO, Berkman BE. Pandemic Influenza: Ethics, Law, and the Public's Health. *Adm Law Rev* [Internet]. 2007;59(1):121–75. Available from: <https://scholarship.law.georgetown.edu/facpub/449/>
70. Présidence de la République du Bénin, Secrétariat général du Gouvernement. Compte rendu du conseil des ministres du 01 sept. 2021 [Internet]. Secrétariat général du Gouvernement; 2021 Sep [cited 2023 Mar 27]. Available from: <https://sgg.gouv.bj/cm/2021-09-01/#ii-mesures-urgentes-faire-face-persistence-pandemie-covid-19>.
71. Addadzi-Koom ME. “No Jab, No Entry”: A Constitutional and Human Rights Perspective on Vaccine Mandates in Ghana. *Health Hum Rights J* [Internet]. 2022 Oct 17;24(2):47–58. Available from: <https://www.hhrjournal.org/2022/10/no-jab-no-entry-a-constitutional-and-human-rights-perspective-on-vaccine-mandates-in-ghana/>
72. Odiegwu M. Compulsory vaccination helps conquer fears in Nigeria [Internet]. Gavi. 2022 [cited 2023 Mar 29]. Available from: <https://www.gavi.org/vaccineswork/compulsory-vaccination-helps-conquer-fears-nigeria>
73. Tilley H. COVID-19 across Africa: Colonial Hangovers, Racial Hierarchies, and Medical Histories. *J West Afr Hist* [Internet]. 2020 Sep 1 [cited 2022 May 27];6(2):155–79. Available from: <https://doi.org/10.14321/jwestafrihist.6.2.0155>
74. American Association for the International Commission of Jurists. Siracusa Principles on the Limitation and Derogation Provisions in the International Covenant on Civil and Political Rights [Internet]. Apr, 1985. Available from: <https://www.icj.org/wp-content/uploads/1984/07/Siracusa-principles-ICCPR-legal-submission-1985-eng.pdf?msckid=2e24a32fcfa911ec863ea614d45bf001>

75. Turcotte-Tremblay AM, Ridde V. A friendly critical analysis of Kass's ethics framework for public health. *Can J Public Health* [Internet]. 2016 Mar 1;107(2):e209–11. Available from: <https://doi.org/10.17269/cjph.107.5160>
76. Ba MF, Faye A, Kane B, Diallo AI, Junot A, Gaye I, et al. Factors associated with COVID-19 vaccine hesitancy in Senegal: A mixed study. *Hum Vaccines Immunother*. 2022 Nov 30;18(5):2060020.
77. De Maeseneer J, van Weel C, Egilman D, Mfenyana K, Kaufman A, Sewankambo N. Strengthening primary care: addressing the disparity between vertical and horizontal investment. *Br J Gen Pract J R Coll Gen Pract*. 2008 Jan;58(546):3–4.
78. World Health Organization. World malaria report 2021 [Internet]. World Health Organization; 2021. Available from: <https://reliefweb.int/sites/reliefweb.int/files/resources/978924004049-eng.pdf>
79. Meldrum A. African Union buys 270 million vaccine doses for continent. *AP News* [Internet]. 2021 Jan 13; Available from: <https://apnews.com/article/pandemics-africa-cybil-ramaphosa-south-africa-coronavirus-pandemic-996bb9cbe3d7a859e4fb656f38162db1>
80. Mustafa Diab M, Zimmerman A, Dixit S, Mao W, Bharali I, Kristoffersen A, et al. The Cost of Procuring and Delivering COVID-19 Vaccines in Low- and Middle-Income Countries: A Model of Projected Resource Needs [Internet]. 2021. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3824690
81. Orangi S, Kairu A, Ngatia A, Ojal J, Barasa E. Examining the unit costs of COVID-19 vaccine delivery in Kenya. *BMC Health Serv Res*. 2022 Apr 4;22(1):439.
82. World Health Organization. Global Health Expenditure Database [Internet]. Available from: <https://apps.who.int/nha/database/Home/Index/en>
83. UNICEF and World Health Organization. UNICEF and WHO warn of 'perfect storm' of conditions for measles outbreaks, affecting children [Internet]. Joint News Release. 2022. Available from: <https://www.who.int/news/item/27-04-2022-unicef-and-who-warn-of-perfect-storm-of-conditions-for-measles-outbreaks-affecting-children>
84. Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. *Value Health J Int Soc Pharmacoeconomics Outcomes Res*. 2016 Dec;19(8):929–35.
85. Jo Y, Kagujje M, Johnson K, Dowdy D, Hangoma P, Chiliukutu L, et al. Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia. *PLOS ONE* [Internet]. 2021 Sep 9;16(9):e0256531. Available from: <https://doi.org/10.1371/journal.pone.0256531>
86. OECD Statistics. Creditor Reporting System [Internet]. Organisation for Economic Co-operation and Development; 2022 [cited 2022 Jul 20]. Available from: <https://stats.oecd.org/Index.aspx?DataSetCode=CRS1>
87. Brown GW, Tacheva B, Shahid M, Rhodes N, Schäferhoff M. Global health financing after COVID-19 and the new Pandemic Fund [Internet]. Brookings. 2022 [cited 2023 Jan 24]. Available from: <https://www.brookings.edu/blog/future-development/2022/12/07/global-health-financing-after-covid-19-and-the-new-pandemic-fund/>

88. Micah AE, Cogswell IE, Cunningham B, Ezoe S, Harle AC, Maddison ER, et al. Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050. *The Lancet* [Internet]. 2021 Oct 9;398(10308):1317–43. Available from: <https://www.sciencedirect.com/science/article/pii/S0140673621012587>
89. Diptyanusa A, Zablon KN. Addressing budget reduction and reallocation on health-related resources during COVID-19 pandemic in malaria-endemic countries. *Malar J*. 2020 Nov 16;19(1):411.
90. McQuaid CF, Vassall A, Cohen T, Fiekert K, White RG. The impact of COVID-19 on TB: a review of the data. *Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis*. 2021 Jun 1;25(6):436–46.
91. Formenti B, Gregori N, Crosato V, Marchese V, Tomasoni LR, Castelli F. The impact of COVID-19 on communicable and non-communicable diseases in Africa: a narrative review. *Infez Med*. 2022;30(1):30–40.
92. Abor PA, Abor JY. Implications of COVID-19 Pandemic for Health Financing System in Ghana. *J Health Manag* [Internet]. 2020 Dec 1 [cited 2022 Jul 21];22(4):559–69. Available from: <https://doi.org/10.1177/0972063420983096>
93. Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, et al. Identifying and combating the impacts of COVID-19 on malaria. *BMC Med* [Internet]. 2020 Jul 30;18(1):239. Available from: <https://doi.org/10.1186/s12916-020-01710-x>
94. Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott AJ, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. *Lancet Respir Med*. 2022 Jun;10(6):603–22.
95. Eghtessadi R, Mukandavire Z, Mutenherwa F, Cuadros D, Musuka G. Safeguarding gains in the sexual and reproductive health and AIDS response amidst COVID-19: The role of African civil society. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020 Nov;100:286–91.
96. World Health Organization. The impact of the COVID-19 pandemic on noncommunicable disease resources and services: results of a rapid assessment [Internet]. 2020. Available from: <https://apps.who.int/iris/handle/10665/334136>
97. World Health Organization. Neglected tropical diseases: impact of COVID-19 and WHO's response – 2021 update [Internet]. WHO; 2021 Sep. Available from: <https://www.who.int/publications/i/item/who-wer9638-461-468>
98. Azizatunnisa' L, Cintyamena U, Bura V, Surya A, Wibisono H, Ahmad RA, et al. Maintaining Polio-Free Status in Indonesia During the COVID-19 Pandemic. *Glob Health Sci Pract* [Internet]. 2022 Feb 3; Available from: <http://www.ghspjournal.org/content/early/2022/02/04/GHSP-D-21-00310.abstract>
99. Bell D, Paul E. Vaccine equity or health equity? *J Glob Health Econ Policy*. 2022;

Review – COVAX – Time to reconsider the strategy and its target

Reviewer #2: The authors have addressed the comments I made in the previous round.

On the human rights argument, I would still be hesitant to include it, as it seems at could be read as it was COVAX pushing for coercion and lack of informed consent. These practices could related to a set of other factors. I have not seen evidence that this is the case, and it goes against material published by the COVAX agencies on voluntary vaccination

Authors' response: We have revised the two paragraphs on the human rights argument on pages 6-7 (please see the track change version). We have added some references to support our argumentation.

Please also note that we have updated reference #32 since the pre-print has been published (changed and new references are marked in yellow).

COVAX – Time to reconsider the strategy and its target

Elisabeth Paul (last/corresponding author) is an active member of the Technical Panel Review of the Global Fund and of the Independent Review Committee of Gavi. However, this paper was written in total independence from these institutions. The authors declare no conflict of interest.

Journal Pre-proofs